Generic placeholder image

Combinatorial Chemistry & High Throughput Screening

Editor-in-Chief

ISSN (Print): 1386-2073
ISSN (Online): 1875-5402

Meta-Analysis

The Role of Dehydroepiandrosterone in Improving in vitro Fertilization Outcome in Patients with DOR/POR: A Systematic Review and Meta- Analysis

Author(s): Jing Wang, Bowen Liu, Jing Wen and Bing Qu*

Volume 26, Issue 5, 2023

Published on: 22 September, 2022

Page: [916 - 927] Pages: 12

DOI: 10.2174/1386207325666220820164357

Price: $65

Abstract

Background and Objective: Although many trials have evaluated the use of dehydroepiandrosterone to improve outcomes in poor responders undergoing assisted reproductive technology treatment, evidence supporting this approach is controversial. We aimed to conduct a systematic review and meta-analysis of existing published data to further elucidate and supplement the use of Dehydroepiandrosterone (DHEA) to improve the effectiveness of vitro fertilization in patients with diminished ovarian reserve or adverse ovarian reactions.

Methods: PubMed, Embase, Cochrane Library, and the Web of Science databases were searched through December 2020. Oocyte yield, metaphase II oocytes, fertilized oocytes, top-quality embryos, clinical pregnancy rate, ongoing pregnancy rate, and live birth rate were analyzed as relative outcomes. Meta-analysis was performed and fitted to both fixed-effects models and random-effects models.

Results: Eight prospective randomized controlled studies, five prospective case-control studies, and three retrospective cohort studies were conducted with a total of 1998 participants. Meta-analyses of these studies showed a significantly higher number of oocytes retrieved (WMD 1.09, 95% CI 0.38 to 1.80), metaphase II oocytes (WMD 0.78, 95% CI 0.16 to 1.40), fertilized oocytes (WMD 0.84, 95% CI 0.42 to 1.26), top-quality embryos (WMD 0.60, 95% CI 0.34 to 0.86), clinical pregnancy rate (RR 1.35, 95% CI 1.13 to 1.61), and ongoing pregnancy rate (RR 1.82, 95% CI 1.34 to 2.46), although there was no difference in live birth rate (RR 1.35, 95% CI 0.94 to 1.94) in the DHEA supplementation groups compared with that in the control groups.

Conclusion: Oral DHEA supplementation appears to improve some IVF outcomes. On the basis of this limited evidence, we conclude that further studies are required to provide sufficient data.

Keywords: Dehydroepiandrosterone, diminished ovarian reserve, poor ovarian response, in vitro fertilization, intracytoplasmic sperm injection, Follicle-Stimulating Hormone (FSH).

Graphical Abstract
[1]
Barad, D.H.; Weghofer, A.; Gleicher, N. Age-specific levels for basal follicle-stimulating hormone assessment of ovarian function. Obstet. Gynecol., 2007, 109(6), 1404-1410.
[http://dx.doi.org/10.1097/01.AOG.0000264065.37661.a0] [PMID: 17540814]
[2]
Sunkara, S.K.; Tuthill, J.; Khairy, M.; El-Toukhy, T.; Coomarasamy, A.; Khalaf, Y.; Braude, P. Pituitary suppression regimens in poor responders undergoing IVF treatment: A systematic review and meta-analysis. Reprod. Biomed. Online, 2007, 15(5), 539-546.
[http://dx.doi.org/10.1016/S1472-6483(10)60386-0] [PMID: 18028745]
[3]
Nagaoka, S.I.; Hassold, T.J.; Hunt, P.A. Human aneuploidy: Mechanisms and new insights into an age-old problem. Nat. Rev. Genet., 2012, 13(7), 493-504.
[http://dx.doi.org/10.1038/nrg3245] [PMID: 22705668]
[4]
Ferraretti, A.P.; La Marca, A.; Fauser, B.C.; Tarlatzis, B.; Nargund, G.; Gianaroli, L. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: The Bologna criteria. Hum. Reprod., 2011, 26(7), 1616-1624.
[http://dx.doi.org/10.1093/humrep/der092] [PMID: 21505041]
[5]
Pandian, Z.; McTavish, A.R.; Aucott, L.; Hamilton, M.P.; Bhattacharya, S. Interventions for ‘poor responders’ to controlled ovarian hyper stimulation (COH) in in vitro fertilisation (IVF). Cochrane Database Syst. Rev., 2010, (1), CD004379.
[http://dx.doi.org/10.1002/14651858.CD004379.pub3] [PMID: 20091563]
[6]
Burger, H.G. Androgen production in women. Fertil. Steril., 2002, 77(Suppl. 4), S3-S5.
[http://dx.doi.org/10.1016/S0015-0282(02)02985-0] [PMID: 12007895]
[7]
Zangmo, R.; Singh, N.; Kumar, S.; Vanamail, P.; Tiwari, A. Role of dehydroepiandrosterone in improving oocyte and embryo quality in IVF cycles. Reprod. Biomed. Online, 2014, 28(6), 743-747.
[http://dx.doi.org/10.1016/j.rbmo.2014.01.019] [PMID: 24745834]
[8]
Casson, P.R.; Lindsay, M.S.; Pisarska, M.D.; Carson, S.A.; Buster, J.E. Dehydroepiandrosterone supplementation augments ovarian stimulation in poor responders: A case series. Hum. Reprod., 2000, 15(10), 2129-2132.
[http://dx.doi.org/10.1093/humrep/15.10.2129] [PMID: 11006185]
[9]
Barad, D.; Gleicher, N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum. Reprod., 2006, 21(11), 2845-2849.
[http://dx.doi.org/10.1093/humrep/del254] [PMID: 16997936]
[10]
Barad, D.; Brill, H.; Gleicher, N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J. Assist. Reprod. Genet., 2007, 24(12), 629-634.
[http://dx.doi.org/10.1007/s10815-007-9178-x] [PMID: 18071895]
[11]
Wiser, A.; Gonen, O.; Ghetler, Y.; Shavit, T.; Berkovitz, A.; Shulman, A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: A randomized prospective study. Hum. Reprod., 2010, 25(10), 2496-2500.
[http://dx.doi.org/10.1093/humrep/deq220] [PMID: 20729538]
[12]
Weissman, A.; Horowitz, E.; Ravhon, A.; Golan, A.; Levran, D. Dehydroepiandrosterone supplementation increases baseline follicular phase progesterone levels. Gynecol. Endocrinol., 2011, 27(12), 1014-1017.
[http://dx.doi.org/10.3109/09513590.2011.569611] [PMID: 21500990]
[13]
Traish, A.M.; Kang, H.P.; Saad, F.; Guay, A.T. Dehydroepiandrosterone (DHEA)-a precursor steroid or an active hormone in human physiology. J. Sex. Med., 2011, 8(11), 2960-2982.
[http://dx.doi.org/10.1111/j.1743-6109.2011.02523.x] [PMID: 22032408]
[14]
Borman, E.; Check, J.H.; Mitchell-Williams, J.; Cohen, R. No evidence to support the concept that low serum dehydroepiandrosterone (DHEA) sulfate (s) levels are associated with less oocyte production or lower pregnancy rates. Clin. Exp. Obstet. Gynecol., 2012, 39(4), 429-431.
[PMID: 23444734]
[15]
DerSimonian, R; Laird, N Meta-analysis in clinical trials revisited. Contemp Clin Trials, 2015, 45(Pt A), 139-145.
[http://dx.doi.org/10.1016/j.cct.2015.09.002]
[16]
Lewis, S.; Clarke, M. Forest plots: Trying to see the wood and the trees. BMJ, 2001, 322(7300), 1479-1480.
[http://dx.doi.org/10.1136/bmj.322.7300.1479] [PMID: 11408310]
[17]
Higgins, J.P.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med., 2002, 21(11), 1539-1558.
[http://dx.doi.org/10.1002/sim.1186] [PMID: 12111919]
[18]
Artini, P.G.; Simi, G.; Ruggiero, M.; Pinelli, S.; Di Berardino, O.M.; Papini, F.; Papini, S.; Monteleone, P.; Cela, V. DHEA supplementation improves follicular microenviroment in poor responder patients. Gynecol. Endocrinol., 2012, 28(9), 669-673.
[http://dx.doi.org/10.3109/09513590.2012.705386] [PMID: 22835219]
[19]
Moawad, A.; Shaeer, M. Long-term androgen priming by use of dehydroepiandrosterone (DHEA) improves IVF outcome in poor-responder patients. A randomized controlled study. Middle East Fertil. Soc. J., 2012, 17(4), 268-274.
[http://dx.doi.org/10.1016/j.mefs.2012.11.002]
[20]
Kara, M.; Aydin, T.; Aran, T.; Turktekin, N.; Ozdemir, B. Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve? Eur. J. Obstet. Gynecol. Reprod. Biol., 2014, 173, 63-65.
[http://dx.doi.org/10.1016/j.ejogrb.2013.11.008] [PMID: 24331115]
[21]
Yeung, T.W.; Chai, J.; Li, R.H.; Lee, V.C.; Ho, P.C.; Ng, E.H. A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders. Fertil. Steril., 2014, 102(1), 108-115.e1.
[http://dx.doi.org/10.1016/j.fertnstert.2014.03.044] [PMID: 24796766]
[22]
Kotb, M.M.; Hassan, A.M. AwadAllah, A.M. Does dehydroepiandrosterone improve pregnancy rate in women undergoing IVF/ICSI with expected poor ovarian response according to the Bologna criteria? A randomized controlled trial. Eur. J. Obstet. Gynecol. Reprod. Biol., 2016, 200, 11-15.
[http://dx.doi.org/10.1016/j.ejogrb.2016.02.009] [PMID: 26963897]
[23]
Jing, F.; Jiang, H.; Lu, L.; Xin, A.; Sun, Y.; Sun, X. Effect of dehydroepiandrosterone supplementation on the embryo quality and follicular fluid markers in patients with diminished ovarian reserve. Chinese Journal of Reproduction and Contraception, 2017, 37(8), 607-613.
[24]
Narkwichean, A.; Maalouf, W.; Baumgarten, M.; Polanski, L.; Raine-Fenning, N.; Campbell, B.; Jayaprakasan, K. Efficacy of Dehydroepiandrosterone (DHEA) to overcome the effect of ovarian ageing (DITTO): A proof of principle double blinded randomized placebo controlled trial. Eur. J. Obstet. Gynecol. Reprod. Biol., 2017, 218, 39-48.
[http://dx.doi.org/10.1016/j.ejogrb.2017.09.006] [PMID: 28934714]
[25]
Vlahos, N.; Papalouka, M.; Triantafyllidou, O.; Vlachos, A.; Vakas, P.; Grimbizis, G.; Creatsas, G.; Zikopoulos, K. Dehydroepiandrosterone administration before IVF in poor responders: A prospective cohort study. Reprod. Biomed. Online, 2015, 30(2), 191-196.
[http://dx.doi.org/10.1016/j.rbmo.2014.10.005] [PMID: 25498594]
[26]
Jirge, P.R.; Chougule, S.M.; Gavali, V.G.; Bhomkar, D.A. Impact of dehydroepiandrosterone on clinical outcome in poor responders: A pilot study in women undergoing in vitro fertilization, using bologna criteria. J. Hum. Reprod. Sci., 2014, 7(3), 175-180.
[http://dx.doi.org/10.4103/0974-1208.142477] [PMID: 25395742]
[27]
Lin, L.T.; Cheng, J.T.; Wang, P.H.; Li, C.J.; Tsui, K.H. Dehydroepiandrosterone as a potential agent to slow down ovarian aging. J. Obstet. Gynaecol. Res., 2017, 43(12), 1855-1862.
[http://dx.doi.org/10.1111/jog.13456] [PMID: 28892223]
[28]
Hu, Q.; Hong, L.; Nie, M.; Wang, Q.; Fang, Y.; Dai, Y.; Zhai, Y.; Wang, S.; Yin, C.; Yang, X. The effect of dehydroepiandrosterone supplementation on ovarian response is associated with androgen receptor in diminished ovarian reserve women. J. Ovarian Res., 2017, 10(1), 32.
[http://dx.doi.org/10.1186/s13048-017-0326-3] [PMID: 28472976]
[29]
Al-Turki, H.A. Dehydroepiandrosterone supplementation in women undergoing assisted reproductive technology with poor ovarian response. A prospective case-control study. J. Int. Med. Res., 2018, 46(1), 143-149.
[http://dx.doi.org/10.1177/0300060517720005] [PMID: 28758852]
[30]
Xu, B.; Li, Z.; Yue, J.; Jin, L.; Li, Y.; Ai, J.; Zhang, H.; Zhu, G. Effect of dehydroepiandrosterone administration in patients with poor ovarian response according to the Bologna criteria. PLoS One, 2014, 9(6), e99858.
[http://dx.doi.org/10.1371/journal.pone.0099858] [PMID: 24932478]
[31]
Chern, C.U.; Tsui, K.H.; Vitale, S.G.; Chen, S.N.; Wang, P.H.; Cianci, A.; Tsai, H.W.; Wen, Z.H.; Lin, L.T. Dehydroepiandrosterone (DHEA) supplementation improves in vitro fertilization outcomes of poor ovarian responders, especially in women with low serum concentration of DHEA-S: A retrospective cohort study. Reprod. Biol. Endocrinol., 2018, 16(1), 90.
[http://dx.doi.org/10.1186/s12958-018-0409-z] [PMID: 30223902]
[32]
Chen, S.N.; Tsui, K.H.; Wang, P.H.; Chern, C.U.; Wen, Z.H.; Lin, L.T. Dehydroepiandrosterone supplementation improves the outcomes of in vitro fertilization cycles in older patients with diminished ovarian reserve. Front. Endocrinol. (Lausanne), 2019, 10, 800.
[http://dx.doi.org/10.3389/fendo.2019.00800] [PMID: 31803144]
[33]
Surrey, E.S.; Schoolcraft, W.B. Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. Fertil. Steril., 2000, 73(4), 667-676.
[http://dx.doi.org/10.1016/S0015-0282(99)00630-5] [PMID: 10731523]
[34]
Fritz, M.A.; Speroff, L. Hormone biosynthesis, metabolism, and mechanism of action and Regulation of the menstrual cycle.In: Clinical gynecologic endocrinology and infertility, 8th; Lippincott Williams & Wilkins: Philadephia, PA, 2011.
[35]
Goswami, S.K.; Das, T.; Chattopadhyay, R.; Sawhney, V.; Kumar, J.; Chaudhury, K.; Chakravarty, B.N.; Kabir, S.N. A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: A preliminary report. Hum. Reprod., 2004, 19(9), 2031-2035.
[http://dx.doi.org/10.1093/humrep/deh359] [PMID: 15217999]
[36]
Mamas, L.; Mamas, E. Premature ovarian failure and dehydroepiandrosterone. Fertil. Steril., 2009, 91(2), 644-646.
[http://dx.doi.org/10.1016/j.fertnstert.2007.11.055] [PMID: 18321501]
[37]
Minghetti, P.; Cilurzo, F.; Casiraghi, A.; Montanari, L.; Santoro, A. Development of patches for the controlled release of dehydroepiandrosterone. Drug Dev. Ind. Pharm., 2001, 27(7), 711-717.
[http://dx.doi.org/10.1081/DDC-100107328] [PMID: 11694019]
[38]
Ravaglia, G.; Forti, P.; Maioli, F.; Sacchetti, L.; Nativio, V.; Scali, C.R.; Mariani, E.; Zanardi, V.; Stefanini, A.; Macini, P.L. Dehydroepiandrosterone-sulfate serum levels and common age-related diseases: Results from a cross-sectional Italian study of a general elderly population. Exp. Gerontol., 2002, 37(5), 701-712.
[http://dx.doi.org/10.1016/S0531-5565(01)00232-7] [PMID: 11909687]
[39]
Ethun, K.F.; Wood, C.E.; Parker, C.R., Jr; Kaplan, J.R.; Chen, H.; Appt, S.E. Effect of ovarian aging on androgen biosynthesis in a cynomolgus macaque model. Climacteric, 2012, 15(1), 82-92.
[http://dx.doi.org/10.3109/13697137.2011.571321] [PMID: 21864136]
[40]
Neves, A.R.; Montoya-Botero, P.; Polyzos, N.P. The role of androgen supplementation in women with diminished ovarian reserve: Time to randomize, not meta-analyze. Front. Endocrinol. (Lausanne), 2021, 12, 653857.
[http://dx.doi.org/10.3389/fendo.2021.653857] [PMID: 34079524]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy